Use of inhibitors of the KQTI channel and methods of controlling and treating diseases caused by helminths and ectoparasites

US6335363B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Uwe Gerlach · Hattersheim, DE
• Joachim Hofmann · Bad Camberg, DE
• Hans-Jochen Lang · Hofheim, DE
• Aguan Wei · Saint Louis, US

Key dates

• Filing date: Dec 16, 1999
• Grant date: Jan 1, 2002
• Expiry date: Dec 16, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P33/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of inhibitors of the KQT1 channel for preparing a medicament for treating diseases caused by helminths and ectoparasitesInhibitors of the KQT1 channel are a novel way of destroying helminths and ectoparasites. For this reason, blockers of the cellular KQT1 channel, which is present in helminths and ectoparasites, are used for preparing a medicament for the treatment of vertebrates and humans infested by helminths or ectoparasites. These KQT1 blockers are used as medicaments on their own or in combination with other medicaments and therapeutic measures.Inhibitors of the KQT1 channel are likewise a novel mechanism of action for phytoparasites such as insects, arachnids, molluscs and nematodes, and consequently, they are used for preparing a crop protection composition.